))
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
Manage episode 435582822 series 3560609
内容由Jacqueline Stone and Oncololgy News Central提供。所有播客内容（包括剧集、图形和播客描述）均由 Jacqueline Stone and Oncololgy News Central 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. From how to “choose the right patient for the right treatment at the right time” to important toxicity concerns, Dr. Hamilton shares her “elevator pitch” to patients when it comes to ADCs. “I think a very easy way to really talk about the activity at this point is just the fact that they’re beating naked chemotherapy. So they are performing better than chemotherapy and, for the most part, comparing favorably in terms of side effects for patients as well.”
Dr. Hamilton reported various financial relationships.
Dr. Figlin reported various financial relationships.
127集单集
分享
